Brief: Active Biotech Gets Approval To Resume Enrolment In Hovon 172 MF Study
13/05/2026 10:31
May 13 (Reuters) - Active Biotech AB publ ACTI.ST: ACTIVE BIOTECH: EUROPEAN REGULATORY APPROVAL OBTAINED TO RESUME ENROLMENT IN THE HOVON 172 MF STUDY EVALUATING TASQUINIMOD IN MYELOFIBROSIS AND CONDUCTED IN COLLABORATION BETWEEN ACTIVE BIOTECH, ONCODE AND HOVON RECEIVES POSITIVE FEEDBACK FROM EUROPEAN REGULATORS ON TASQUINIMOD MYELOFIBROSIS STUDY HOVON TASQUINIMOD STUDY CLEARED TO RESUME PATIENT RECRUITMENT IN NETHERLANDS AND GERMANY Source text: ID:nMFNb41khG Further company coverage: ACTI.ST (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 772 0920;))